Ralliant (NYSE:RAL) Rating Increased to Hold at BMO Capital Markets

Ralliant (NYSE:RAL) was upgraded by stock analysts at BMO Capital Markets to a “hold” rating in a research report issued to clients and investors on Monday,Zacks.com reports.

RAL has been the topic of a number of other research reports. Oppenheimer raised their target price on Ralliant from $50.00 to $65.00 and gave the company an “outperform” rating in a report on Wednesday, May 13th. Wall Street Zen raised Ralliant from a “hold” rating to a “buy” rating in a research report on Saturday. Evercore started coverage on Ralliant in a research note on Tuesday, June 9th. They set an “outperform” rating and a $80.00 target price on the stock. Vertical Research downgraded shares of Ralliant from a “buy” rating to a “hold” rating and set a $65.00 price target on the stock. in a report on Wednesday, May 27th. Finally, Citigroup increased their price target on shares of Ralliant from $70.00 to $81.00 and gave the company a “buy” rating in a research report on Monday, July 13th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $71.45.

Ralliant Trading Down 0.6%

NYSE RAL opened at $69.78 on Monday. The business has a 50 day moving average price of $65.62 and a 200-day moving average price of $53.28. Ralliant has a 52 week low of $37.27 and a 52 week high of $75.41. The company has a quick ratio of 1.05, a current ratio of 1.61 and a debt-to-equity ratio of 0.73. The company has a market cap of $7.81 billion and a price-to-earnings ratio of -6.38.

Ralliant (NYSE:RAL) last issued its quarterly earnings data on Tuesday, May 12th. The company reported $0.57 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.49 by $0.08. Ralliant had a negative net margin of 58.55% and a positive return on equity of 12.49%. The firm had revenue of $534.60 million during the quarter. The company’s quarterly revenue was up 11.0% compared to the same quarter last year. Ralliant has set its FY 2026 guidance at 2.530-2.690 EPS and its Q2 2026 guidance at 0.580-0.640 EPS. As a group, equities analysts expect that Ralliant will post 2.64 earnings per share for the current fiscal year.

Institutional Trading of Ralliant

A number of institutional investors have recently modified their holdings of the business. Allworth Financial LP grew its stake in Ralliant by 134.4% in the 4th quarter. Allworth Financial LP now owns 511 shares of the company’s stock valued at $26,000 after buying an additional 293 shares in the last quarter. Rothschild Investment LLC raised its holdings in Ralliant by 98.1% during the 4th quarter. Rothschild Investment LLC now owns 612 shares of the company’s stock valued at $31,000 after acquiring an additional 303 shares during the period. Keybank National Association OH lifted its position in shares of Ralliant by 1.6% during the fourth quarter. Keybank National Association OH now owns 19,667 shares of the company’s stock worth $1,001,000 after acquiring an additional 305 shares in the last quarter. UMB Bank n.a. lifted its position in shares of Ralliant by 49.6% during the fourth quarter. UMB Bank n.a. now owns 983 shares of the company’s stock worth $50,000 after acquiring an additional 326 shares in the last quarter. Finally, Maryland State Retirement & Pension System boosted its holdings in shares of Ralliant by 1.5% in the fourth quarter. Maryland State Retirement & Pension System now owns 21,940 shares of the company’s stock worth $1,117,000 after acquiring an additional 329 shares during the period.

Ralliant Company Profile

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.